In the rapidly evolving landscape of oncology, precision is the cornerstone of progress. A leading biopharmaceutical company ...

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped ...

Novocure (NVCR) recognized first non-small cell lung cancer revenues ahead of schedule, with 92 Optune Lua prescriptions for NSCLC received in ...

Discover NovoCure's Q1 2025 earnings insights, including Optune Lua's NSCLC progress, global market growth, and strong revenue performance.

Data suggest that taletrectinib “provides clinically meaningful tumor shrinkage and prolonged disease control as a treatment option for advanced ROS1+ NSCLC, regardless of treatment history,” ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Given that only a small fraction of patients with cancer exhibits specific markers making them eligible for effective ...

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due ...

NSCLC patients who stopped immunotherapy due to side effects still showed lasting disease control and survival benefits..

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due ...

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due to ...